Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development

Immunological Reviews

Volumn 183, Issue , 2001, Pages 127-140

  Locher, Christopher P ^a,b   Witt, Stephanie A ^a   Herndier, Brian G ^b   Tenner Racz, Klara ^c   Racz, Paul ^c   Levy, Jay A ^a  

^a Division of Hematology and Oncology   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATION; CD8 ANTIGEN; CD86 ANTIGEN; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LIPOSOME; VAXFECTIN; VIRULENCE FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; BABOON; CELLULAR IMMUNITY; CHRONIC DISEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE MODEL; DRUG DESIGN; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBIOLOGY; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; FEMALE; HIV INFECTIONS; HIV-2; HUMANS; IMMUNITY, NATURAL; MALE; MODELS, ANIMAL; PAPIO;

EID: 0035664793     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.1830111.x     Document Type: Review

References (101)

1. Animal models for HIV infection and AIDS, memorandum from a WHO meeting
2. The value of primate models for studying human immunodeficiency virus pathogenesis
3. Baboons as an animal model for genetic studies of common human disease
4. Nonhuman primate models to evaluate vaccine safety and immunogenicity
5. The baboon: Microbiology, clinical chemistry and some hematological aspects
6. An analysis of features of pathogenesis in two animal models of Ebola virus infection
7. Protection of non-murine mammals against encephalomyocarditis virus using a genetically engineered Mengo virus
8. Antibody response in baboons (Papio cynocephalus anubis) to a commercially available encephalomyocarditis virus vaccine
9. The simian origins of the pathogenic human T-cell lymphotropic virus type I
10. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons
11. Characterization of the MN gp120 HIV-1 vaccine: Antigen binding to alum
12. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope
13. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1
14. Induction of antibody response by DNA immunization of newborn baboons against influenza virus
15. An evaluation of the possibility of obtaining an inactivated vaccine against Lassa fever
16. Pathogenicity of SAD rabies vaccine given orally in chacma baboons (Papio ursinus)
17. Innocuity studies of SAG-2 oral rabies vaccine in various Zimbabwean wild non-target species
18. Stimulation of rotavirus IgA, IgG and neutralising antibodies in baboon milk by parenteral vaccination
19. The postvaccinal reaction in hamadryas baboons to the administration of attenuated strain 15 of the Venezuelan equine encephalomyelitis virus
20. Isolation and study of an anthrax protective antigen. V. The dynamics of immunity in vaccination with a concentrated, purified sorbed chemical anthrax vaccine
21. An experimental study of the immunogenic and protective properties of Coxiella burnetii strain M-44 and a live enteral vaccine against Q fever
22. P-fimbriae vaccines. II. Cross reactive protection against pyelonephritis
23. The immunological efficacy of Francisella tularensis outer membranes for hamadryas baboons
24. The baboon as a non-human primate model for assessing the effects of maternal immunization with Haemophilus influenzae type b polysaccharide vaccines
25. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine
26. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate
27. Assessment of the effectiveness of different methoods of immunization with live plague vaccine EB in aerosol infections
28. Leishmania major: The suitability of East African non-human primates as animal models for cutaneous leishmaniasis
29. Protective immunity to Schistosoma mansoni induced in the olive baboon Papio anubis by the irradiated cercaria vaccine
30. The baboon as a non-human primate model of human schistosome infection
31. Production in Escherichia coli, purification and immunogenicity of acrosomal protein SP-10, a candidate contraceptive vaccine
32. Reversible contraception in female baboons immunized with a synthetic epitope of sperm-specific lactate dehydrogenase
33. Failure of female baboons (Papio anubis) to conceive following immunization with recombinant non-human primate zona pellucida glycoprotein-B expressed in Escherichia coli
34. Human chorionic gonadotropin as a target for cancer vaccines
35. The baboon in medical research
36. IgG subclasses in the baboon (Papio cynocephalus)
37. Chromatographic fractionation of rhesus monkey (Macaca mulatta) IgG subclasses using DEAE cellulose and protein A-sepharose
38. Comparison and characterization of immunoglobulin G subclasses among primate species
39. Cytogenetic and fertility studies of a rheboon, rhesus macaque (Macaca mulatta) X baboon (Papio hamadryas) cross: Further support for a single karyotype nomenclature
40. Immunoreactive cytokines within primates
41. Flow cytometric detection of intracellular cytokine/chemokine in rhesus, baboon and cynomolgus macaque monkey peripheral blood mononuclear cells with anti-human cytokine/chemokine monoclonal antibodies
42. Persistent infection of chimpanzees with human T-lymphotropic virus type III/LAV: A potential model for acquired immunodeficiency syndrome
43. Infection of Macaca nemestrina by human immunodeficiency virus type-1
44. Differential replication and pathogenic effects of HIV-1 and HIV-2 in Macaca nemestrina
45. HIV-2 in rhesus monkeys: Serological, virological and clinical results
46. BEN, a novel HIV-2 isolate
47. An AIDS-like condition induced in baboons by HIV-2
48. Human immunodeficiency virus-2 infection in baboons is an animal model for human immunodeficiency virus pathogenesis in humans
49. + cell depletion in Macaca nemestrina
50. Pathogenic and immunologic consequences of HIV-2 serial passage in baboons
51. Identification of two homologs of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species
52. A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus
53. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
54. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
55. Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals
56. Molecular cloning of the human immunodeficiency virus subtype 2 strain HIV-2UC2
57. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay
58. Biologic heterogeneity of human immunodeficiency virus type 2 (HIV-2)
59. Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient
60. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
61. + T-cell antiviral response
62. Transient virus infection and pathogenesis of a new HIV type 2 isolate, UC12, in baboons
63. Persistent infection of baboon and rhesus monkeys with different strains of HIV-2
64. Prevalence of antibodies against simian immunodeficiency virus (SIV) and simian T-lymphotropic virus (STLV) in a colony of non-human primates in Kenya, East Africa
65. Prevalence of antibodies to SIV in baboons in their native habitat
66. Simian immunodeficiency viruses (SIVs) from eastern and southern Africa: Detection of a SIVagm variant from a chacma baboon
67. Prevalence and transmission of simian immunodeficiency virus and simian T-cell leukemia virus in a semi-free-range breeding colony of mandrills in Gabon
68. Infection of baboons with simian/human immunodeficiency viruses
69. Infection of baboons with a simian immunodeficiency virus/HIV-1 chimeric virus constructed with an HIV-1 Thai subtype E envelope
70. + cells suppress human immunodeficiency virus replication by inhibiting viral transcription
71. + cells from HIV-2-infected baboons control HIV replication
72. + lymphocytes from HIV-2-infected baboons
73. + T lymphocytes from macaques immunized with live attenuated SIV
74. Mucosal antibody expression following rapid SIV (Mne) dissemination in intrarectally infected Macaca nemestrina
75. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles
76. Genetic immunization is a simple method for eliciting an immune response
77. DNA vaccines
78. DNA vaccines for immunodeficiency viruses
79. Multivalent minigene vaccines against infectious disease
80. The evolution of DNA vaccines
81. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
82. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
83. Control of a mucosal challenge and prevention of AIDS in rhesus macaques by a multiprotein DNA/MVA vaccine
84. + T-cell-depleted rhesus macaques
85. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12
86. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens
87. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by co-delivery of various cytokine genes
88. Development of multicomponent DNA vaccination strategies against HIV
89. DNA shuffling and vaccines
90. Protection against mycoplasma infection using expression-library immunization
91. DNA-based vaccines: Extending the technology
92. Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses
93. Codon usage limitation in the expression of HIV-1 envelope glycoprotein
94. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene
95. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines
96. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
97. + cell suppression of HIV replication
98. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens
99. Cationic microparticles: A potent delivery system for DNA vaccines
100. DNA-polycation nanospheres as non-viral gene delivery vehicles